Ustekinumab use in lactation: drug pharmacokinetics and normal development in exposed infants
Lay Summary Ustekinumab was excreted into breast milk at very low levels after both subcutaneous and intravenous administration. Infant serum levels declined despite ongoing breastfeeding, and long-term follow-up showed normal development and no adverse events, supporting continued breastfeeding during ustekinumab treatment.
Authors
- Philip O. Anderson (ORCID: https://orcid.org/0000-0001-5649-217X)
- Christina L. Balmer
- Julie Korgaard
- Signe Wildt
- Jens Kjeldsen
Institutions
- Aarhus Municipality (DK)
- Odense University Hospital (DK)
- Hvidovre Hospital (DK)
- Aarhus University Hospital (DK)
- University of Montana (US)
- Aalborg University (DK)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1093/ibd/izaf336
- Primary Topic
- Pregnancy and Medication Impact
- Type
- article
- Field-Weighted Citation Impact
- 0.00